Technology

Moleculin Biotech

$1.07
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.11 (+11.45%) Today
$0.00 (0.00%) As of 10:01 PM UTC after-hours

Why Robinhood?

You can buy or sell MBRX and other stocks, options, and ETFs commission-free!

About MBRX

Moleculin Biotech, Inc. Common Stock, also called Moleculin Biotech, is a clinical stage pharmaceutical company, which focuses on the development of oncology drug candidates. Its Annamycin product candidate helps in the treatment of relapsed or refractory acute myeloid leukemia. The company's preclinical small molecule portfolios focus on the modulation of hard-to-target tumor cell signaling mechanisms and the metabolism of tumors. Moleculin Biotech was founded by Walter V. Klemp, Donald H. Picker and Waldemar Priebe on July 28, 2015 and is headquartered in Houston, TX. The listed name for MBRX is Moleculin Biotech, Inc. Common Stock.

CEO
Walter V. Klemp
Employees
16
Headquarters
Houston, Texas
Founded
2015
Market Cap
63.56M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
2.98M
High Today
$1.10
Low Today
$0.965
Open Price
$0.971
Volume
9.82M
52 Week High
$1.97
52 Week Low
$0.323

Collections

MBRX Earnings

-$0.17
-$0.11
-$0.06
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 18, Pre-Market

You May Also Like

AEHR
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure